Atovaquone pharmaceutical compositions
AssigneeSmithKline Beecham Corporation
InventorAlan Roy Dearn
Life of this patent
Estimating the term…
Abstract
The invention relates to a process for the production of microfluidized particles of atovaquone having improved bioavailability.
Claims12
Small particles of atovaquone wherein at least 90% of the particles of atovaquone have a volume diameter in the range 0.1-3 μm.
Small particles of atovaquone wherein the particles of atovaquone have been microfluidized.
Microfluidized particles of atovaquone wherein at least 90% of the microfluidized particles of atovaquone have a volume diameter in the range 0.1-3 μm.
A pharmaceutical composition comprising particles of atovaquone and one or more pharmaceutically acceptable carriers therefor wherein at least 90% of the particles have a volume diameter in the range of 0.1-3 μm.
A method for the treatment and/or prophylaxis of protozoal infections in mammals which comprises administering to said mammals an effective amount of particles of atovaquone and one or more pharmaceutically acceptable carrier therefor wherein at least 90% of the particles have a volume diameter in the range of 0.1-3 μm.
Dependencies are inferred from the claim text.